0001209191-22-024136.txt : 20220412 0001209191-22-024136.hdr.sgml : 20220412 20220412161017 ACCESSION NUMBER: 0001209191-22-024136 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220408 FILED AS OF DATE: 20220412 DATE AS OF CHANGE: 20220412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flannelly Barry P CENTRAL INDEX KEY: 0001615842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 22822383 MAIL ADDRESS: STREET 1: ROUTE 141 AND HENRY CLAY ROAD CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-08 0 0000879169 INCYTE CORP INCY 0001615842 Flannelly Barry P 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP & General Manager US Common Stock 2022-04-08 4 M 0 20516 68.62 A 87808 D Common Stock 2022-04-08 4 S 0 20516 83.01 D 67292 D Common Stock 2022-04-08 4 M 0 21348 72.27 A 88640 D Common Stock 2022-04-08 4 S 0 21348 84.00 D 67292 D Common Stock 2022-04-08 4 S 0 881 82.96 D 66411 D Common Stock 2022-04-08 4 S 0 1248 82.96 D 65163 D Non-Qualified Stock Option (right to buy) 68.62 2022-04-08 4 M 0 20516 0.00 D 2028-07-01 Common Stock 20516 0 D Non-Qualified Stock Option (right to buy) 72.27 2022-04-08 4 M 0 21348 0.00 D 2029-01-03 Common Stock 21348 0 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Includes an aggregate of 64,148 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years. /s/ Barry Flannelly 2022-04-12